Hikma Introduces New Arthritis Treatment To The US Market

Hikma Pharmaceuticals PLC, a global pharmaceutical company, has launched Indomethacin Suppositories (50mg) in the United States. Hikma stands second in the generic manufacturing market. This launch expands Hikma’s product portfolio and provides doctors and patients with more treatment options.

The medication is approved for several conditions, including moderate to severe rheumatoid arthritis, which includes acute flares, ankylosing spondylitis, osteoarthritis, acute painful shoulder (bursitis or tendinitis), and acute gouty arthritis. According to IQVIA, sales of Indomethacin Suppositories (50mg) in the US reached approximately $57 million in the 12 months ending October 2024.

In the U.S., Hikma, known for its huge range of non-injectable products, specializes in complex technologies such as nasal sprays and operates a manufacturing facility in Columbus, Ohio. The product has received FDA approval for marketing in the United States, but this approval is limited to the US market.